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Currently,  Neisseria  meningitidis  serogroup  C (MenC)  is  the  major  cause  of bacterial  meningitis  in  Brazil,
affecting  mainly  teenagers  and adults  due  to  the  lack  of routine  public  vaccination  of these  age  groups.
The  goal  of  this  study  was  to investigate  the  bactericidal  antibody  response  and the  development  of CD4+
T  cell  memory  during  the convalescent  phase  of  patients  infected  with  N.  menigitidis.  Most  (85.7%)  of  the
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patients  developed  a protective  antibody  response  against  MenC  and  57% also  responded  to  N.  meningitidis
serogroup  B.  We  detected  a  signiﬁcant  CD4+ T central  memory  (TCM) response  to  meningococcal  outer
membrane  proteins.
© 2014  Elsevier  Ltd. All  rights  reserved.. Introduction
Neisseria meningitidis is the major cause of bacterial meningitis
orldwide [1]. In Brazil, meningococcal disease (MD) is endemic,
ith periodic outbreaks [2]. Case fatality rates are as high as 18–20%
f cases [2–4]. Since 2000, Brazil has experienced an increase in
erogroup C MD,  which accounted for 70% of reported cases in 2013
4]. Since the end of the 90’s, sero/serosubtype 23:P1.14-6, clone ST-
03, has been the prevalent phenotype/genotype of MenC strains
solated in the country [5].
Complement-mediated serum bactericidal antibody (SBA),
nduced by nasopharyngeal colonization or vaccination, confers
rotection against meningococci, but little is known about the gen-
ration of memory CD4+ T cells after disease or vaccination [6,7].
he development of immune memory mediated by CD4+ T cells is
entral to long-lasting protective immunity [8]. Understanding the
echanism by which MD induces a protective immune response
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264-410X/© 2014 Elsevier Ltd. All rights reserved.is essential to improving the long-term efﬁcacy of meningococcal
vaccines.
We investigated the presence of SBA, total immunoglobulin
(total Ig) response to C polysaccharide (C-PS) and the distribution of
CD4+ T central memory (TCM), T effector memory (TEM) and T effec-
tor cells (TEff) subsets speciﬁc to N. Meningitidis in MD  convalescent
individuals.
2. Subjects and methods
2.1. Study participants and specimen collection
Between August 2010 and January 2012, we were able to collect
blood samples of seven patients from Instituto Estadual de Infec-
tologia São Sebastião, Rio de Janeiro, RJ, Brazil. Diagnosis of MD
was based on clinical symptoms and latex agglutination reaction
(PASTOREXTM MENINGITIS, Bio-Rad, Marnes-la-Coquette France).
Serogroup C N. meningitidis (MenC) was  identiﬁed in the cere-
brospinal ﬂuid (CSF) of all patients, aged 13–61 years, median and
mean of 18 and 25 years old, respectively.
All adult patients or participant’s parents or legal guardians
provided written informed consent. The study was approved by
Hospital Universitário Pedro Ernesto (State University of Rio de
5 ine 32
J
2
d
d
1
e
d
U
2
(
C
u
(
s
2
o
r
h
l
1
t
6
c
f
o
k
t
s
w
1
v
b
i
2
b
C
P
(
w
m
a
T
T146 A.C. Cruz et al. / Vacc
aneiro) Research Ethics Committee (Protocol number CEP/HUPE:
743/2010).
Following informed consent, blood was taken at the time of
ischarge (convalescent phase), mean of 9.4 days (range of 5–17
ays) after hospital entrance (Table 1). A maximum volume of
0 ml  heparinised blood was available for the separation of periph-
ral blood mononuclear cells (PBMC). PBMCs were separated by
ensity-gradient centrifugation over Histopaque® (Sigma, St. Louis,
SA) and used freshly. Plasma was collected and frozen at −20 ◦C.
.2. Meningococcal strains
For bactericidal assay we used two MenC strains: N79/96
C:2b:P1.10) and N753/00 (C:23:P1.14-6) and the serogroup B
uban (MenB) strain (Cu385/83, B:4,7:P1.19,15) as target strains.
For the preparation of outer membrane vesicles (OMVs) to be
sed in the CD4+ memory T cell analysis we used N79/96, H355/75
B:15:P1.19,15) and its variant PorA− strain [9]. The origin of these
trains was previously described [10].
.3. Bactericidal assay
SBA titers against MenC and MenB were measured as previ-
usly described with some modiﬁcations [11,12]. Brieﬂy, the ﬁnal
eaction mixture contained 25 l of diluted test serum previously
eat inactivated at 56 ◦C for 30 min, 12.5 l of human serum that
acked detectable intrinsic bactericidal activity diluted at 1:2, and
2.5 l of log phase meningococci (about 5 × 103 CFU/ml). The bac-
ericidal reaction was carried out at 37 ◦C for 30 min  (MenB) or
0 min  (MenC). The bactericidal titer was deﬁned as the recipro-
al of the serum dilution causing ≥50% killing. The positive control
or each assay consisted of post-vaccination human sera with previ-
usly determined bactericidal titer. The complement-independent
illing control consisted of heat-inactivated unknown test sera in
he presence of heat-inactivated complement and bacteria. Serum
amples showing complement-independent killing were treated
ith 20 U ml−1 of penicillinase (Sigma, St. Louis, USA) at 37 ◦C per
 h which eliminated all complement-independent killing [13]. Pre-
ious data showed that treatment with penicillinase did not alter
actericidal antibody titers of sera that did not show complement-
ndependent killing (data not shown).
.4. ELISA
ELISA analysis for the C-PS antigen was performed as described
y Gheesling et al. [14]. The puriﬁed C-PS was obtained from
enter for Disease Control and Prevention, Atlanta, Georgia.
eroxidase-conjugated goat anti-total human immunoglobulin
IgG + IgM + IgA, Kirkegaard & Perry Laboratories, Maryland, USA)
as used. As an internal antibody standard for total Ig deter-
ination, a twofold dilution series of a positive post-vaccination
dult serum was used in all experiments. The anti-C-PS titer was
able 1
otal IgC-PS and bactericidal antibody titers against MenC strains (N79/96 and N753/00) 
Patient Age (years) Time post-onset of disease (days)
1 61 17 
2  37 11 
3  13 06 
4  13 09 
5  18 09 
6  14 09 
7  19 05 
a ELISA total Ig antibodies (IgG + IgM + IgA) against C-PS. The anti-C-PS titer was  determ (2014) 5145–5148
determined as the dilution in which OD490 reading was at least
0.2 U. For each serum the OD490 was extrapolated from a sigmoidal
dose–response (variable slope) curve generated from the OD dilu-
tion curve using the software GraphPad Prism 4. Negative control
consisted of serum from a healthy child not immunized against
meningococci with anti-C-PS titer of less than 100 U.
2.5. FACS analysis
Freshly prepared PBMC (1 × 106 cells/100 l) were plated in 96-
well ﬂat-bottom plate in complete RPMI medium, stimulated with
OMVs at 50 g/ml or PHA (Sigma) at 10 g/ml or un-stimulated
during incubation for 3 h at 37 ◦C in 5% CO2 atmosphere. PBMC
were pre-incubated with human serum (2 l/well) for 15 min  at
4 ◦C before staining the cells for surface markers. Cells were stained
for a panel of cell surface markers including ﬂuorescein isothiocya-
nate (FITC)-conjugated CD4; phycoerythrin (PE)-conjugated CCR7;
PerCP-conjugated CD69; and APC-conjugated CD45RA (all from BD
Biosciences Pharmingen, San Diego, CA) for 30 min at 4 ◦C. Samples
were analyzed on a Becton Dickinson FACScalibur ﬂow cytometer.
On acquisition, a gate was set around the lymphocyte population
on a forward scatter versus side scatter dot plot, and 10,000-gated
events were collected for each sample. Data analysis was performed
using FlowJo software, version 7.6.4. CD4+ T-cells were gated from
the lymphocyte population and then analyzed for the expression
of CD45RA, CCR7 and CD69. Appropriate isotype matched controls
(BD) were run in parallel for each sample.
2.6. Statistical analysis
The levels of signiﬁcance of the differences between groups
were examined by nonparametric tests; Maan–Whitney test
(unpaired samples) or Wilcoxon matched pair test (paired sam-
ples). These analyses were performed with a GraphPad-Prism
software, version 4.02. P < 0.05 was taken as signiﬁcant.
3. Results and discussion
3.1. Bactericidal antibody and total Ig response
As shown in Table 1 the majority of patients (85.7%) showed a
protective SBA response (titer ≥ 4) against at least one of the two
MenC strains. Only one individual (number 4) did not show a mea-
sured SBA response at the moment of hospital discharge (9 days
post-onset of disease). Five (71%) of 7 patients had SBA titers ≥ 4
against both MenC strains (Table 1). Strain variability in suscepti-
bility to meningococcal antibody has also been observed previously
[11] and indicates the importance of using more than one strain in
SBA assay.
Sera of 3 patients (numbers 1, 5 and 6) also demonstrated SBA to
the MenB strain but in lower titer compared with the MenC strains.
Individual number 3 showed similar response to MenC and MenB
and a MenB strain (Cu385/83) in MD  convalescent sera.
Bactericidal antibody titer; strain Total Iga (U-DO490nm)
N79/96 N753/00 Cu385/83 C-PS
64 32 8 718.5
32 8 2 318
4 8 4 1353.5
< 2 < 2 2 284.0
32 64 8 270.5
2 256 16 1243.5
4 8 2 1495.0
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trains (titers of 4 and 8). Despite differences in times of incubation
f bactericidal reaction for MenB (30 min) and MenC (60 min), these
esults suggest that antibody titers against MenB could be due to
he presence of common epitopes among different serogroups of
eningococcal strains and/or the presence of antibodies of differ-
nt speciﬁcities recognizing these strains. These antibodies could
ave been induced by disease but also by carriage of N. meningitidis
r related organisms.
Concerning to the ELISA antibodies (Table 1), all individuals
howed a positive response (>100 U), including patient number 4
ho had no bactericidal antibodies. The response was heteroge-
eous and there was no signiﬁcant correlation (r = −0.04 to −0.16,
 > 0.05) with MenC-SBA, probably due to the small number of sam-
les and/or the presence of IgG with no bactericidal activity.
Therefore, in agreement with literature [6] these data indicated
hat most of the convalescent patients had a protective bactericidal
ntibody response. Variations in antibody titers can be attributed
o different causes including the time of blood collection after the
nset of disease.
.2. Memory T-cell response
To distinguish the putative naive and memory CD4+ T-cell
ubsets, we analyzed the expression of CD45RA and CCR7. The
aive subset is CD45RA+CCR7+, whereas the memory subsets are
D45RA−CCR7+ (TCM) or CD45RA−CCR7− (TEM). Because effector
erminally differentiated T-cells can re-express CD45RA, we  called
 cells CD45RA+CCR7− as TEff (Effector cells) [8,15].
Fig. 1 shows the frequency of CD4+ T cell memory subsets in
BMC of convalescent patients before and after speciﬁc stimulus
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ig. 1. Frequency (%) of CD4+ memory T-cells in PBMC obtained about 10 days after hosp
ith  OMVs from strains N79/96 (C:2b:P1.10), H355/75 (B:15:P1.19,15) and its variant 
emory CD4+ T-cells (TEM; CD4+CD45RA−/+CCR7−) and (C) effector T cells (TEff; CD4+CD4 (2014) 5145–5148 5147
with OMVs from strains N79/96 (MenC), H355/75 (MenB) and
H355/75 PorA−. We  observed a similar proportion of TCM (median
from 35% to 38%, Fig. 1A) and TEM (median from 29% to 34%, Fig. 1B).
About 3.2% (median) of CD4+ T cells met  the phenotype of TEff cells
(Fig. 1C). The presence of antigenic stimulus did not alter the fre-
quency of CD4+ T cell memory subsets signiﬁcantly (P > 0.05 for all
comparisons related to different strains and T cell populations).
Fig. 2 shows the activation status of CD4+ T cells as determined
by the expression of CD69, a marker for recent cell activation
[16,17], after stimulus with OMVs from MenC (N79/96 strain,
Fig. 1A); MenB (H355 strain, Fig. 1B) and from the variant PorA-
strain (Fig. 1C).
Comparing with TEM and TEff subsets, TCM was the subset
of CD4+ memory T cells with the highest (P < 0.05) frequency
of activation after stimulus with OMVs from different strains
(Fig. 2A–C). Interestingly, OMVs from MenC strain showed the high-
est ability to activate CD4+ TCM cells (median of 15%, Fig. 1A),
compared with MenB (median of 8.9%, P = 1.0) and the PorA−
strain (median of 6.4%, P = 0.06). These results indicated that outer
membrane proteins (OMPs) from meningococci are important to
induce the main arm of CD4+ T cell memory, the TCM subset.
These cells have high proliferative potential and capacity to secrete
effector cytokines after a second exposure to antigenic stimulus
[8,15].
A important but not statistically signiﬁcant reduction in fre-
quency of CD69+-TCM (median of 6.4%) was  detected when using
the PorA− strain, compared to MenB (median of 8.9%, P > 0.05) and
specially MenC OMVs (median of 15%, P = 0.06) stimulus. These data
suggests that PorA contributes to the induction of memory CD4+
TCM cell response after meningococcal disease. Since patients were
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PorA− . (A) Central memory CD4+ T-cells (TCM; CD4+CD45RA−CCR7+), (B) effector
5RA+CCR7). Lines represent the median values.
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Fig. 2. Median percentage of CD4+ memory T cells expressing the CD69 molecule in PBMC of MD  convalescent patients. Cells were stimulated for 3 h or not with OMVs and %
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nside  the ﬁgures represent P values.
nfected by MenC strains and showed a strong TCM response to
enB strains, these results also suggest that there is a possibility
f the existence of shared CD4+-epitopes among OMPs of different
erogroups. The identiﬁcation of any common pan-meningococcal
pitopes would be of special interest for vaccine development. Due
o the small sample size and wide variation in T cell response, fur-
her investigations should be conducted to conﬁrm the suggestive
ndings of this study.
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